1
|
Liang C, Yang JB, Lin XY, Xie BL, Xu YX, Lin S, Xu TW. Recent advances in the diagnostic and therapeutic roles of microRNAs in colorectal cancer progression and metastasis. Front Oncol 2022; 12:911856. [PMID: 36313731 PMCID: PMC9607901 DOI: 10.3389/fonc.2022.911856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2022] [Accepted: 09/26/2022] [Indexed: 11/13/2022] Open
Abstract
Colorectal cancer (CRC) is the third most common malignancy in the world and one of the leading causes of cancer death; its incidence is still increasing in most countries. The early diagnostic accuracy of CRC is low, and the metastasis rate is high, resulting in a low survival rate of advanced patients. MicroRNAs (miRNAs) are a small class of noncoding RNAs that can inhibit mRNA translation and trigger mRNA degradation, and can affect a variety of cellular and molecular targets. Numerous studies have shown that miRNAs are related to tumour progression, immune system activity, anticancer drug resistance, and the tumour microenvironment. Dysregulation of miRNAs occurs in a variety of malignancies, including CRC. In this review, we summarize the recent research progress of miRNAs, their roles in tumour progression and metastasis, and their clinical value as potential biomarkers or therapeutic targets for CRC. Furthermore, we combined the roles of miRNAs in tumorigenesis and development with the therapeutic strategies of CRC patients, which will provide new ideas for the diagnosis and treatment of CRC.
Collapse
Affiliation(s)
- Chen Liang
- Department of Digestive Tumours, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
| | - Jing-Bo Yang
- Department of Digestive Tumours, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
| | - Xin-Yi Lin
- Department of Digestive Tumours, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
| | - Bi-Lan Xie
- Department of Digestive Tumours, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
| | - Yun-Xian Xu
- Department of Digestive Tumours, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
| | - Shu Lin
- Centre of Neurological and Metabolic Research, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
- Group of Neuroendocrinology, Garvan Institute of Medical Research, Sydney, NSW, Australia
- *Correspondence: Tian-Wen Xu, ; Shu Lin,
| | - Tian-Wen Xu
- Department of Digestive Tumours, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
- *Correspondence: Tian-Wen Xu, ; Shu Lin,
| |
Collapse
|
2
|
Maisano D, Mimmi S, Dattilo V, Marino F, Gentile M, Vecchio E, Fiume G, Nisticò N, Aloisio A, de Santo MP, Desiderio G, Musolino V, Nucera S, Sbrana F, Andò S, Ferrero S, Morandi A, Bertoni F, Quinto I, Iaccino E. A novel phage display based platform for exosome diversity characterization. NANOSCALE 2022; 14:2998-3003. [PMID: 35141731 DOI: 10.1039/d1nr06804k] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
We present an innovative approach allowing the identification, isolation, and molecular characterization of disease-related exosomes based on their different antigenic reactivities. The designed strategy could be immediately translated into any disease in which exosomes are involved. The identification of specific markers and their subsequent association with exosome subtypes, together with the possibility to engineer target-guided exosome-like particles, could represent the key for the effective adoption of exosomes in clinical practice.
Collapse
Affiliation(s)
- Domenico Maisano
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Selena Mimmi
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Vincenzo Dattilo
- Genetics Units, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Fabiola Marino
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | | | - Eleonora Vecchio
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Giuseppe Fiume
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Nancy Nisticò
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Annamaria Aloisio
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | | | - Giovanni Desiderio
- CNR/Nanotec, Physics Department, University of Calabria, Rende, CS, Italy
| | - Vincenzo Musolino
- IRC-FSH Department of Health Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy
| | - Saverio Nucera
- IRC-FSH Department of Health Sciences, University "Magna Græcia" of Catanzaro, Catanzaro, Italy
| | | | | | - Simone Ferrero
- Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Turin, Italy
| | - Andrea Morandi
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
| | - Francesco Bertoni
- IOR, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
| | - Ileana Quinto
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| | - Enrico Iaccino
- Department of Experimental and Clinical Medicine, University "Magna Graecia of Catanzaro", Catanzaro, Italy.
| |
Collapse
|
3
|
Buhagiar A, Seria E, Borg M, Borg J, Ayers D. Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance. CANCER DRUG RESISTANCE (ALHAMBRA, CALIF.) 2021; 4:934-945. [PMID: 35582382 PMCID: PMC8992439 DOI: 10.20517/cdr.2021.62] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 09/01/2021] [Accepted: 09/24/2021] [Indexed: 11/27/2022]
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide. It has also been demonstrated that over the last ten years the incidence of CRC among younger people below the age of 50 is also increasing. Screening for colorectal cancer is of utmost importance; the rationale behind screening is to target the malignancy and reduce the incidence and mortality of the disease. Diagnostic methods to screen for incidence or relapse are therefore a requisite to detect cancer as early as possible. Scientific findings demonstrate that many deaths are due to lack of screening and therefore early identification will lead to greater survivability. In colorectal cancer, diagnostic tests include liquid biopsy biomarkers. Since the discovery of microRNAs (miRNAs), many studies have demonstrated the relationship between miRNAs and the various sub-types of CRC. Several miRNAs have been identified after analysing serum or plasma samples in patients, and such miRNAs were found to be significantly dysregulated. Such findings place the possibility of miRNAs to be at the epicentre of novel diagnostic techniques for CRC identification and sub-type stratification, including other characteristics associated with CRC development such as patient prognosis. The following review serves to underline the latest findings for miRNAs with such potential for routine diagnostic employment in CRC diagnostics and treatments.
Collapse
Affiliation(s)
- Alfred Buhagiar
- Faculty of Medicine and Surgery, University of Malta, Msida 2080, Malta
| | - Elisa Seria
- Centre for Molecular Medicine and Biobanking, University of Malta, Msida 2080, Malta
| | - Miriana Borg
- Faculty of medical sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
| | - Joseph Borg
- Faculty of Health Sciences, University of Malta, Msida 2080, Malta
| | - Duncan Ayers
- Centre for Molecular Medicine and Biobanking, University of Malta, Msida 2080, Malta
- Faculty of Biology, Medicine and Health Sciences, The University of Manchester, Manchester M13 9PL, UK
| |
Collapse
|